BRPI0518328A2 - agente de contraste, composiÇço farmacÊutica, uso de um agente de contraste, mÉtodo para gerar imagens realÇadas de um corpo animal ou humano, e, kit para a preparaÇço de um composiÇço radiofarmacÊutica - Google Patents

agente de contraste, composiÇço farmacÊutica, uso de um agente de contraste, mÉtodo para gerar imagens realÇadas de um corpo animal ou humano, e, kit para a preparaÇço de um composiÇço radiofarmacÊutica

Info

Publication number
BRPI0518328A2
BRPI0518328A2 BRPI0518328-6A BRPI0518328A BRPI0518328A2 BR PI0518328 A2 BRPI0518328 A2 BR PI0518328A2 BR PI0518328 A BRPI0518328 A BR PI0518328A BR PI0518328 A2 BRPI0518328 A2 BR PI0518328A2
Authority
BR
Brazil
Prior art keywords
contrast agent
animal
kit
preparation
human body
Prior art date
Application number
BRPI0518328-6A
Other languages
English (en)
Inventor
Dagfinn Lovhaug
Morten Eriksen
Hege B Fjerdingstad
Andrew Healey
Original Assignee
Ge Healthcare As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ge Healthcare As filed Critical Ge Healthcare As
Publication of BRPI0518328A2 publication Critical patent/BRPI0518328A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0056—Peptides, proteins, polyamino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0032—Methine dyes, e.g. cyanine dyes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/085—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier conjugated systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/14—Peptides, e.g. proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Steroid Compounds (AREA)

Abstract

AGENTE DE CONTRASTE, COMPOSIÇçO FARMACÊUTICA, USO DE UM AGENTE DE CONTRASTE, MÉTODO PARA GERAR IMAGENS REALÇADAS DE UM CORPO ANIMAL OU HUMANO, E, KIT PARA A PREPARAÇçO DE UMA COMPOSIÇçO RADIOFARMACÊUTICA. Um agente de contraste da fórmula geral (I): Z~ 1~-L-V-Z~ 2~ (I) em que pelo menos um de Z1 e Z2 está presente e são porções repórter iguais ou diferentes detectáveis na formação de imagem in vivo do corpo animal ou humano, V é uma porção alvejadora com afinidade de ligação para áreas de formação de colágeno, L é uma ligação covalente, um biomodíficador ou uma porção alvejadora.
BRPI0518328-6A 2004-11-22 2005-11-21 agente de contraste, composiÇço farmacÊutica, uso de um agente de contraste, mÉtodo para gerar imagens realÇadas de um corpo animal ou humano, e, kit para a preparaÇço de um composiÇço radiofarmacÊutica BRPI0518328A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
NO20045081 2004-11-22
PCT/NO2005/000435 WO2006054904A2 (en) 2004-11-22 2005-11-21 Contrast agents to target extracellular matrix

Publications (1)

Publication Number Publication Date
BRPI0518328A2 true BRPI0518328A2 (pt) 2008-11-11

Family

ID=36182407

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0518328-6A BRPI0518328A2 (pt) 2004-11-22 2005-11-21 agente de contraste, composiÇço farmacÊutica, uso de um agente de contraste, mÉtodo para gerar imagens realÇadas de um corpo animal ou humano, e, kit para a preparaÇço de um composiÇço radiofarmacÊutica

Country Status (17)

Country Link
US (1) US8182790B2 (pt)
EP (2) EP1814598B1 (pt)
JP (2) JP5116480B2 (pt)
KR (1) KR20070091609A (pt)
CN (1) CN101107016B (pt)
AT (1) ATE494913T1 (pt)
AU (1) AU2005307195A1 (pt)
BR (1) BRPI0518328A2 (pt)
CA (1) CA2586621A1 (pt)
DE (1) DE602005025911D1 (pt)
ES (1) ES2358745T3 (pt)
IL (1) IL182898A0 (pt)
MX (1) MX2007006050A (pt)
NO (1) NO20073039L (pt)
RU (1) RU2007118385A (pt)
WO (1) WO2006054904A2 (pt)
ZA (1) ZA200705043B (pt)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0610395D0 (en) * 2006-05-25 2006-07-05 Ge Healthcare Ltd Novel imaging agents
WO2008026040A2 (en) * 2006-08-28 2008-03-06 Ge Healthcare Limited 68ga-labeled peptide-based radiopharmaceuticals
JP2008266194A (ja) * 2007-04-19 2008-11-06 Hiroshi Tanaka 分子プローブの原料として有用な新規有機化合物
GB0722650D0 (en) * 2007-11-19 2007-12-27 Ge Healthcare Ltd Novel imaging method
EP2224959B1 (en) 2007-12-13 2015-02-25 INSERM (Institut National de la Santé et de la Recherche Médicale) Polypeptides, cyclic polypeptides and pharmaceutical comprising thereof for non invasive specific imaging of fibrosis
ES2658852T3 (es) 2008-01-18 2018-03-12 Visen Medical, Inc. Agentes de imaginología fluorescentes
US8110402B2 (en) 2008-05-13 2012-02-07 University Of Kansas Metal abstraction peptide (MAP) tag and associated methods
GB0814722D0 (en) * 2008-08-12 2008-09-17 Ge Healthcare Ltd Treatment monitoring
GB0910013D0 (en) * 2009-06-10 2009-07-22 Ge Healthcare Ltd PET imaging of fibogenesis
KR100991716B1 (ko) * 2009-10-22 2010-11-04 경북대학교 산학협력단 광학영상 조영제, 그 용도 및 장치
CN102504603B (zh) * 2011-10-20 2014-01-29 中国海洋大学 一种多聚物与生物染色剂的偶合物及其制备方法和用途
US9187735B2 (en) 2012-06-01 2015-11-17 University Of Kansas Metal abstraction peptide with superoxide dismutase activity
US20170050989A1 (en) * 2013-12-03 2017-02-23 The General Hospital Corporation Molecular Imaging Probes
CN117623996B (zh) * 2022-08-10 2025-07-22 中国药科大学 一种二价keap1-nrf2抑制剂、制备方法及其医药用途

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4647447A (en) 1981-07-24 1987-03-03 Schering Aktiengesellschaft Diagnostic media
US4615876A (en) * 1983-04-25 1986-10-07 Curators Of The University Of Missouri Macrocyclic complexes of technetium-99m for use as diagnostic radionuclides
US4687659A (en) 1984-11-13 1987-08-18 Salutar, Inc. Diamide-DTPA-paramagnetic contrast agents for MR imaging
US5268486A (en) 1986-04-18 1993-12-07 Carnegie-Mellon Unversity Method for labeling and detecting materials employing arylsulfonate cyanine dyes
US6048982A (en) 1986-04-18 2000-04-11 Carnegie Mellon University Cyanine dyes as labeling reagents for detection of biological and other materials by luminescence methods
ATE145337T1 (de) 1988-05-02 1996-12-15 Phanos Tech Inc Verbindungen, zusammensetzungen und verfahren zum binden von bio-affektions-substanzen an oberflächenmembranen von bioteilchen
GB8903022D0 (en) * 1989-02-10 1989-03-30 Celltech Ltd Chemical compounds
WO1993011120A1 (en) 1991-11-27 1993-06-10 Zynaxis Technologies, Incorporated Compounds, compositions and methods for binding bio-affecting substances to surface membranes of bio-particles
IL129445A0 (en) 1996-10-28 2000-02-29 Nycomed Imaging As Improvements in or relating to diagnostic/therapeutic agents
ATE314097T1 (de) * 1996-10-28 2006-01-15 Amersham Health As Kontrastmittel
CA2278200A1 (en) * 1997-01-29 1998-07-30 Nycomed Imaging As Polymers
WO1999005221A1 (en) 1997-07-28 1999-02-04 Nycomed Amersham Plc Cyanine dyes
US5942637A (en) 1998-03-30 1999-08-24 North Dakota State University Research Foundation Compounds containing tetradecachlorocyclohexasilane dianion
US6852318B1 (en) 1998-05-08 2005-02-08 The Regents Of The University Of California Methods for detecting and inhibiting angiogenesis
PT1075277E (pt) * 1998-05-08 2009-05-08 Univ California Métodos para detectar e inibir a angiogénese
JP2000095758A (ja) * 1998-09-18 2000-04-04 Schering Ag 近赤外蛍光造影剤および蛍光造影方法
US6230777B1 (en) 1999-02-04 2001-05-15 Midmac Systems, Inc. Filter forming and joining apparatus
ATE298763T1 (de) * 2000-04-12 2005-07-15 Amersham Health As Integrinbindende peptidderivate
NO20004795D0 (no) 2000-09-26 2000-09-26 Nycomed Imaging As Peptidbaserte forbindelser
EP1337278A2 (en) * 2000-11-27 2003-08-27 Bristol-Myers Squibb Medical Imaging, Inc. Simultaneous imaging of cardiac perfusion and a vitronectin receptor targeted imaging agent
ES2719088T3 (es) * 2001-07-10 2019-07-08 Ge Healthcare Ltd Compuestos con base peptídica para localizar receptores de integrina
GB0116815D0 (en) * 2001-07-10 2001-08-29 Nycomed Amersham Plc Improved chelator conjugates
GB0206750D0 (en) 2002-03-22 2002-05-01 Amersham Plc Radiofluorination methods
AU2003239030A1 (en) 2002-06-17 2003-12-31 Cartela R & D Ab Methods and uses of the integrin alpha 10 chain, for preventing progression of atherosclerosis plaque formation
US7063158B2 (en) 2003-06-16 2006-06-20 Deepwater Technologies, Inc. Bottom tensioned offshore oil well production riser
NO20033115D0 (no) * 2003-07-08 2003-07-08 Amersham Health As Peptid-baserte forbindelser
GB0317815D0 (en) * 2003-07-30 2003-09-03 Amersham Health As Imaging agents
US7371364B2 (en) 2003-08-15 2008-05-13 Board Of Regents, The University Of Texas System Cyclic peptide and imaging compound compositions and uses for targeted imaging and therapy
EP1699494A2 (en) * 2003-11-24 2006-09-13 GE Healthcare AS Contrast agent imaging angiotensin ii receptors
EP1729823B1 (en) * 2004-03-04 2009-11-04 GE Healthcare AS Conjugates of angiotensin peptidic analogues and chelating agents for diagnosis and therapy
NZ551210A (en) 2004-06-16 2009-10-30 Ge Healthcare As Peptide-based compounds
WO2005123768A1 (en) * 2004-06-16 2005-12-29 Ge Healthcare As Peptide-based compounds

Also Published As

Publication number Publication date
IL182898A0 (en) 2007-08-19
EP1814598A2 (en) 2007-08-08
ES2358745T3 (es) 2011-05-13
KR20070091609A (ko) 2007-09-11
EP2243496A3 (en) 2012-12-26
RU2007118385A (ru) 2008-12-27
WO2006054904A3 (en) 2007-04-05
JP2008520658A (ja) 2008-06-19
MX2007006050A (es) 2007-11-14
CN101107016B (zh) 2011-11-16
ATE494913T1 (de) 2011-01-15
JP5116480B2 (ja) 2013-01-09
EP1814598B1 (en) 2011-01-12
AU2005307195A1 (en) 2006-05-26
DE602005025911D1 (de) 2011-02-24
ZA200705043B (en) 2008-09-25
EP2243496A2 (en) 2010-10-27
JP2012207027A (ja) 2012-10-25
NO20073039L (no) 2007-08-16
US8182790B2 (en) 2012-05-22
US20090208412A1 (en) 2009-08-20
WO2006054904A2 (en) 2006-05-26
CN101107016A (zh) 2008-01-16
CA2586621A1 (en) 2006-05-26

Similar Documents

Publication Publication Date Title
NO20073039L (no) Kontrastmidler
UA103758C2 (ru) Конъюгаты олигомеров инсулина, их композиции и применение
BRPI0515175A (pt) método para radiofluoração, composto, composição radiofarmacêutica, uso de um conjugado radiorrotulado ou um sal do mesmo, método para diagnose ou formação de imagem in vivo de uma doença ou condição associada com a angiogênese, e, método para monitorar o efeito do tratamento de um corpo humano ou animal com um medicamento para combater uma condição associada com cáncer
CY1109151T1 (el) Αντισωματα dr4 και χρησεις αυτων
DK0836380T3 (da) FGF9 som en specifik ligand for FGFR3
WO1998018497A3 (en) Contrast agents
YU72901A (sh) Preparati za primenu u terapiji i dijagnozi raka pluća
BRPI0519195A2 (pt) composiÇço de cuidado oral, e, mÉtodo para prevenir ou tratar cÁrie dental em um indivÍduo humano ou animal
WO2001082975A3 (en) Membrane-permeant peptide complexes for medical imaging
AU6160201A (en) Human polypeptides causing or leading to the killing of cells including lymphoidtumor cells
BR0003987A (pt) Composição laxativa
IL159527A0 (en) Human dr4 antibodies and uses thereof
GT200600001A (es) Uso de colorantes de cianina para el diagnostico de enfermedades proliferativas
SI2157192T1 (sl) Sestavki za diagnozo in terapijo bolezni, povezanih z aberantno ekspresijo Futrinov (R-Spondinov)
BRPI0413974A (pt) combinação, método de tratamento de cáncer em um animal de sangue quente, composição farmacêutica, e, uso de uma combinação
BRPI0416528A (pt) agente de formação de imagem, composição farmacêutica, composição radiofarmacêutica, conjugado, kit para a preparação da composição radiofarmacêutica, e, uso do agente de formação de imagem
CY1109868T1 (el) Cd81 πρωτεϊνη υποδοχεας ηπατιτιδας c
BRPI0416938A (pt) agente de formação de imagem, composição, conjugado, kit para a preparação da composição radiofarmacêutica
BR0115518A (pt) Kit de repinotan
BR0009472A (pt) Antagonistas de lhrh com propriedades desolubilidade aperfeiçoadas
DK1228770T3 (da) Törret kontrastmiddel
ATE425770T1 (de) Kontrastmittel
WO2004002984A3 (fr) Composes de maleimides marques, leur procede de preparation et leur utilisation pour le marquage de macromolecules
BRPI0412453A (pt) uso do ácido ascórbico ou um sal fisiologicamente aceitável do mesmo
GR3020861T3 (en) Mri image enhancement of bone and related tissue using complexes of paramagnetic cations and polyphosphonate ligands

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]